SCHEMBL7140310

SCHEMBL7140310

Fc1ccc(-c2ncc(-c3cccc(CNCCC4=CCCCC4)c3)[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.44
HTR7 P34969 1/20 0.44
HTR6 P50406 1/20 0.44
BACE1 P56817 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CNR2 P34972 3/20 0.38
OPRM1 P35372 2/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
CNR1 P21554 2/20 0.38
HPGDS O60760 1/20 0.38
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8118302 0.92 HTR1A (0.52) HTR1AHTR7HTR6CNR2OPRM1
SCHEMBL7138181 0.83 HPGDS (0.49) BACE1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7141176 0.82 CYP1A2 (0.46) BACE1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7143626 0.80 BACE1 (0.45) BACE1CNR2CNR1HPGDS
SCHEMBL7179734 0.78 BACE1 (0.47) BACE1CNR2CNR1HPGDS
SCHEMBL7140173 0.77 BACE1 (0.43) HTR1ABACE1CNR2CNR1HPGDS
SCHEMBL8110914 0.77 CYP1A2 (0.44) BACE1SMN1; SMN2CNR2CYP1A2CYP2D6
SCHEMBL7138024 0.77 SSTR3 (0.47) BACE1SMN1; SMN2HPGDS
SCHEMBL7135108 0.77 CYP1A2 (0.46) BACE1SMN1; SMN2CNR2CYP1A2CYP2D6
SCHEMBL7143478 0.76 KCNH2 (0.49) BACE1CNR2CYP2D6CNR1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed